Orthocell received a medical device licence from Health Canada, enabling the company to commence sales of its dental-guided bone regeneration product, Striate+, in Canada.

This milestone adds to existing approvals in the US, Europe/UK, Australia, and New Zealand.

"Canadian approval for Striate+ is further validation of Orthocell's expanding global footprint. Approval in this market complements our FDA approval and strengthens the company's position to increase revenue in collaboration with our valued partner BioHorizons," Orthocell Managing Director Paul Anderson remarked.

Striate+ is a collagen membrane used in dental implant procedures to support guided bone regeneration.

BioHorizons, a global dental implant company, will distribute the product in Canada.